The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: an immunoenzymatic and microtomographic study.
- 2021-11-15
- Journal of Periodontology 93(2)
- Giselle A Silva
- A. L. Moreira
- P. Silva
- S. L. Salvador
- R. Casarin
- R. M. Vicente
- Graziele C. Ferreira
- J. E. dos Santos
- F. Furlaneto
- M. Messora
- PubMed: 34374081
- DOI: 10.1002/JPER.21-0285
Abstract
Background: This study evaluated the effects of Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019) in the development of periodontitis (PE), associated or not with metabolic syndrome, (MS) in rats.
Methods: Ninety-six rats were grouped according to a food protocol: high-fat diet for induction of MS or standard diet for the control groups (C). They were subdivided into groups with (+) and without (-) PE, receiving (*) or not (**) probiotic (PROB): C-**, CP-*, PE+**, PEP+*, MS- MSP-*, MSPE+**, and MSPEP+*. PROB administration started on the eighth week of the study and PE was induced on the 14th week by placing ligature on the animals' lower first molars. Euthanasia occurred in the 16th week. Biomolecular analyzes, immunoenzymatic assays, and microtomographic analyses were performed. The data obtained were analyzed statistically (P < 0.05).
Results: The PEP and MSPEP groups showed lower levels of alveolar bone loss when compared with the PE and MSPE groups, respectively (P < 0.05). The immunoenzymatic analysis showed higher levels of interleukin (IL)-1β and a higher receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio in the MSPE group when compared with the MSPEP group (P < 0.05). The PEP group showed lower levels of tumor necrosis factor (TNF)-α and IL-6 when compared with the PE group. The use of PROB attenuated dyslipidemia parameters in animals with MS, with or without PE.
Conclusion: B. lactis HN019 reduced more significantly the severity of PE in rats with MS, modulating both systemic metabolic and immunoinflammatory parameters in periodontal tissues.
Keywords: metabolic syndrome; periodontitis; probiotics.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium animalis subsp. lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Dyslipidemia Parameters | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Interleukin-1β Levels | Beneficial | Small |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Interleukin-6 Levels | Beneficial | Small |
Bifidobacterium animalis subsp. lactis HN019 | Reduced RANKL/OPG Ratio | Beneficial | Small |
Bifidobacterium animalis subsp. lactis HN019 | Reduced TNF-α Levels | Beneficial | Small |
Bifidobacterium lactis HN019 | Improved Immunoinflammatory Markers | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Reduced Dyslipidemia in Metabolic Syndrome | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Reduced Inflammation Levels | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Reduced Severity of Periodontitis | Beneficial | Moderate |